BACKGROUND: The pathogenesis of asthma is believed to reflect antigen-induced airway inflammation leading to the recruitment of eosinophils and activation of mast cells through cell-associated IgE. Controversies persist however, regarding the relative importance of different pathogenic cells and effector molecules. MATERIALS AND METHODS: A variety of gene-targeted mice were examined for the induction of cholinergic airway hyperresponsiveness (AH), allergic airway inflammation, mucus production, and serum IgE reactivity following intratracheal challenge with a potent allergen. AH was determined using whole-body plethysmography following acetylcholine challenge. Where possible, results were confirmed using neutralizing antibodies and cell-specific reconstitution of immune deficient mice. RESULTS: T and B cell-deficient, recombinase-activating-gene-deficient mice (RAG -/-) failed to develop significant allergic inflammation and AH following allergen challenge. Reconstitution of RAG -/- mice with CD4+ T cells alone was sufficient to restore allergen-induced AH, allergic inflammation, and goblet cell hyperplasia, but not IgE reactivity. Sensitized B cell-deficient mice also developed airway hyperreactivity and lung inflammation comparable to that of wild-type animals, confirming that antibodies were dispensable. Treatment with neutralizing anti-IL-4 antibody or sensitization of IL-4-deficient mice resulted in loss of airway hyperreactivity, whereas treatment with anti-IL-5 antibody or sensitization of IL-5-deficient mice had no effect. CONCLUSIONS: In mice, CD4+ T cells are alone sufficient to mediate many of the pathognomonic changes that occur in human asthma by a mechanism dependent upon IL-4, but independent of IL-5, IgE, or both. Clarification of the role played by CD4+ T cells is likely to stimulate important therapeutic advances in treatment of asthma.
BACKGROUND: The pathogenesis of asthma is believed to reflect antigen-induced airway inflammation leading to the recruitment of eosinophils and activation of mast cells through cell-associated IgE. Controversies persist however, regarding the relative importance of different pathogenic cells and effector molecules. MATERIALS AND METHODS: A variety of gene-targeted mice were examined for the induction of cholinergic airway hyperresponsiveness (AH), allergic airway inflammation, mucus production, and serum IgE reactivity following intratracheal challenge with a potent allergen. AH was determined using whole-body plethysmography following acetylcholine challenge. Where possible, results were confirmed using neutralizing antibodies and cell-specific reconstitution of immune deficient mice. RESULTS: T and B cell-deficient, recombinase-activating-gene-deficient mice (RAG -/-) failed to develop significant allergic inflammation and AH following allergen challenge. Reconstitution of RAG -/- mice with CD4+ T cells alone was sufficient to restore allergen-induced AH, allergic inflammation, and goblet cell hyperplasia, but not IgE reactivity. Sensitized B cell-deficient mice also developed airway hyperreactivity and lung inflammation comparable to that of wild-type animals, confirming that antibodies were dispensable. Treatment with neutralizing anti-IL-4 antibody or sensitization of IL-4-deficient mice resulted in loss of airway hyperreactivity, whereas treatment with anti-IL-5 antibody or sensitization of IL-5-deficient mice had no effect. CONCLUSIONS: In mice, CD4+ T cells are alone sufficient to mediate many of the pathognomonic changes that occur in humanasthma by a mechanism dependent upon IL-4, but independent of IL-5, IgE, or both. Clarification of the role played by CD4+ T cells is likely to stimulate important therapeutic advances in treatment of asthma.
Authors: J A Ganzalo; G Q Jia; V Aguirre; D Friend; A J Coyle; N A Jenkins; G S Lin; H Katz; A Lichtman; N Copeland; M Kopf; J C Gutierrez-Ramos Journal: Immunity Date: 1996-01 Impact factor: 31.745
Authors: M Kopf; F Brombacher; P D Hodgkin; A J Ramsay; E A Milbourne; W J Dai; K S Ovington; C A Behm; G Köhler; I G Young; K I Matthaei Journal: Immunity Date: 1996-01 Impact factor: 31.745
Authors: I J Doull; S Lawrence; M Watson; T Begishvili; R W Beasley; F Lampe; T Holgate; N E Morton Journal: Am J Respir Crit Care Med Date: 1996-04 Impact factor: 21.405
Authors: A Oshiba; E Hamelmann; K Takeda; K L Bradley; J E Loader; G L Larsen; E W Gelfand Journal: J Clin Invest Date: 1996-03-15 Impact factor: 14.808
Authors: D B Corry; H G Folkesson; M L Warnock; D J Erle; M A Matthay; J P Wiener-Kronish; R M Locksley Journal: J Exp Med Date: 1996-01-01 Impact factor: 14.307
Authors: Martin Montes; Elin A Jaensson; Aaron F Orozco; Dorothy E Lewis; David B Corry Journal: J Immunol Methods Date: 2006-10-10 Impact factor: 2.303
Authors: Scott M Drouin; Meenal Sinha; Georgia Sfyroera; John D Lambris; Rick A Wetsel Journal: Am J Respir Crit Care Med Date: 2006-01-26 Impact factor: 21.405
Authors: Bing Han; Guoyang Luo; Zheng-Zheng Shi; Roberto Barrios; Donna Atwood; Weili Liu; Geetha M Habib; Richard N Sifers; David B Corry; Michael W Lieberman Journal: Am J Pathol Date: 2002-08 Impact factor: 4.307
Authors: Tianshu Yang; Melissa B Ramocki; Jeffrey L Neul; Wen Lu; Luz Roberts; John Knight; Christopher S Ward; Huda Y Zoghbi; Farrah Kheradmand; David B Corry Journal: Sci Transl Med Date: 2012-12-05 Impact factor: 17.956